This is a clinical research study for people with Stage 4 lung cancer or lung cancer that has returned after treatment. In this study, we want to learn if treatment with two study drugs (ramucirumab and pembrolizumab) works better than usual treatment.

Do you have small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)? Has your lung cancer come back or did not get better with the last treatment you were given? If so, you may be able to take part in a gene therapy research study that uses your own modified immune cells as treatment.

Pancreatic cancer has one of the lowest survival rates for all cancers, but there are some people who achieve long-term survival. We are looking at those patients, with the goal of identifying what are some treatments and experiences that do work. Learning about treatment combinations and unique therapies that have led to success can open doors for where our research should be focused moving forward.

The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Do you have ovarian cancer that has come back after your first round of treatment? if so you may be able to participate in a research study to test if MIRV in combination with bevacizumab as maintenance therapy, can help to prevent your cancer from returning or delaying your cancer's return.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

To determine the difference in change in apoptosis between diagnosis and surgery as a function of ruxolitinib treatment versus placebo, among participants with high-risk or premalignant breast conditions.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Do you have renal cell cancer that has spread beyond your kidney and surgery is not recommended? You may be able to take part in a research study to help us learn if adding radiation therapy to your usual cancer treatment may help your cancer shrink.